Inhibition of carbohydrate-mediated glucagon-like peptide-I (7–36)amide secretion by circulating non-esterified fatty acids
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Two studies were performed to assess the entero-insular axis in simple obesity and the possible effect of variations in the level of circulating non-esterified fatty acids (NEFA) on one of the components of the entero-insular axis, glucagon-like peptide-1 [(7–36) amide]. In the first study, we compared the entero-pancreatic hormone response to oral carbohydrate in obese and lean women. Obese subjects demonstrated hyperinsulinaemia and impaired glucose tolerance but this was not associated with an increased secretion of either glucose-dependent insulinotropic polypeptide or glucagon-like peptide-1 (GLP-1). These findings therefore provide no support for the hypothesis that overactivity of the entero-insular axis contributes to the hyperinsulinaemia seen in obesity. Indeed, the plasma GLP-1 response to carbohydrate was markedly attenuated in obese subjects, confirming previous observations. In the second study, in which carbohydrate-stimulated GLP-1 responses were again evaluated in obese and lean women, circulating NEFA levels were modulated using either heparin (to increase serum NEFA) or acipimox (to reduce serum NEFA). Treatment with acipimox resulted in complete suppression of NEFA levels and in a markedly higher GLP-1 response than the response to carbohydrate alone or to carbohydrate plus heparin. We suggest that higher fasting and postprandial NEFA levels in obesity may tonically inhibit nutrient-mediated GLP-1 secretion, and that this results in attenuation of the GLP-1 response to carbohydrate. However, although serum NEFA levels post-acipimox were similarly suppressed in both lean and obese subjects, the GLP-1 response was again significantly lower in obese subjects, suggesting the possibility of an intrinsic defect of GLP-1 secretion in obesity. The reduction of GLP-1 levels in obesity may be important both in relation to its insulinotropic effect and to its postulated role as a satiety factor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two clinical studies in simple obesity patients found that higher fasting and postprandial NEFA levels, the insulin-promoting effect of GLP-1 and its postulated role as a satiety factor may inhibit nutrition-mediated secretion (23).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [23]
Citations
Cites
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Self-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Attenuated GLP-1 secretion in obesity: cause or consequence
Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
INTRAGASTRIC BALLOON AS AN ARTIFICIAL BEZOAR FOR TREATMENT OF OBESITY
Gyring Nieben, O., & Harboe, H. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90762-0 · Cited by 292
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
“Recently, it was hypothesized that NEFA inhibit the L cell (41).”
BackgroundVerdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
Self-citationVerdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Larsen, P. J., Fledelius, C., Knudsen, L. B., & Tang-Christensen, M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2530 · Cited by 257
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“BN is a recombinant human GLP-1(7-36) acid, obtained by genetic engineering technology, and the amino acid sequence of its active component is the same as that of GLP-1 in the human body.”
BackgroundBrubaker, P. L., & Anini, Y. (2003) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y03-107 · Cited by 220
“Recent studies have also demonstrated that GLP-1 secretion is reduced in obesity (Ranganath et al. 1999; Verdich et al. 2001), as discussed in more detail below.”
BackgroundVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Appetite signaling: From gut peptides and enteric nerves to brain
Näslund, E., & Hellström, P. M. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.017 · Cited by 173
“As mentioned previously, plasma levels of both GLP-1 and PYY are attenuated in the obese after a meal [38–40].”
Hellström, P. M., Geliebter, A., Näslund, E., Schmidt, P. T., Yahav, E. K., Hashim, S. A., & Yeomans, M. R. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041142 · Cited by 149
“It has been reported that the plasma increase of GLP-1 after a meal is attenuated in obese subjects (Ranganath et al. 1996, 1999; Na¨slund et al. 1998 a ).”
Adam, T. C. M., & Westerterp-Plantenga, M. S. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041335 · Cited by 136
“The present findings are different from observations by Ranganath et al. (1996, 1999) and Verdich et al. (2001), who reported a pronounced attenuation of postprandial GLP-1 response in obese subjects.”
ResultDecreased Glucagon‐like Peptide 1 Release after Weight Loss in Overweight/Obese Subjects
Adam, T. C. M., Jocken, J., & Westerterp‐Plantenga, M. S. (2005) · Obesity Research · doi:10.1038/oby.2005.80 · Cited by 91
Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1
Hellström, P. M., & Näslund, E. B. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00618-7 · Cited by 78
Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
Torekov, S. S., Madsbad, S., & Holst, J. J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00860.x · Cited by 72
“It has been suggested that particularly the L-cell responsiveness to carbohydrates is affected (41), and that circulating fatty acids could be responsible (42).”
BackgroundRanganath, L. R. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043232 · Cited by 69
Self-citationThe entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 71
Self-citationPathophysiological Links Between Diabetes and Blood Pressure
Libianto, R., Batu, D., MacIsaac, R. J., Cooper, M. E., & Ekinci, E. I. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.010 · Cited by 67
Adam, T. C. M., Lejeune, M. P. G. M., & Westerterp-Plantenga, M. S. (2006) · British Journal of Nutrition · doi:10.1079/bjn20051614 · Cited by 54
“An increase in plasma NEFA has been found to inhibit carbohydrate-mediated GLP-1 secretion (Ranganath et al. 1996, 1999), so that increased plasma NEFA after weight loss in the present study, might in part contribute to decreased GLP-1 secretion after the standard breakfast.”
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Kil, D. Y., & Swanson, K. S. (2010) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2009.10.004 · Cited by 64
“fatty acid concentrations, often a result of obesity, have been considered factors for blunted GLP-1 response with weight gain.(109,110) However, postprandial GLP-1, glucose, and free fatty acid concentrations have not been strongly correlated in obese”
Sakamoto, E., Seino, Y., Fukami, A., Mizutani, N., Tsunekawa, S., Ishikawa, K., Ogata, H., Uenishi, E., Kamiya, H., Hamada, Y., et al. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00208.x · Cited by 51
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“The former may be a result of impaired L-cell responsiveness to carbohydrates in the obese state, perhaps due to a high level of circulating free fatty acids [46].”
BackgroundThe gut and food intake: an update for surgeons
Näslund, E. B., Hellström, P. M., & Kral, J. G. (2001) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(01)80095-0 · Cited by 42
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“…fatty acids (NEFA), according to Ranganath [115] et al. The insulin-promoting impact of GLP-1, its putative role as a satiety factor, and greater fasting and postprandial NEFA levels may impede nutrition-mediated secretion, according to two clinical trials in patients with simple obesity [116].”
Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight
Wang, F., Yoder, S. M., Yang, Q., Kohan, A. B., Kindel, T. L., Wang, J., & Tso, P. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00351.2013 · Cited by 36
“In obese, nondiabetic humans, GIP secretion has been reported to increase (11, 42) or not change (30, 31, 40), whereas GLP-1 secretion remains unchanged (1, 9, 11, 31, 42) or is attenuated (24, 30, 31, 37, 40).”
BackgroundPotential use of exenatide for the treatment of obesity
Folli, F., & Guardado Mendoza, R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.630660 · Cited by 26
“The mechanism by which obesity reduces GLP-1 secretion is not very well known, but may be related to the insulin resistance associated with weight gain and to an increase in the circulatory levels of carbohydrates and fatty acids [12-14].”
BackgroundForbes, S., Moonan, M., Robinson, S., Anyaoku, V., Patterson, M., Murphy, K. G., Ghatei, M. A., Bloom, S. R., & Johnston, D. G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02172.x · Cited by 24
Kramer, C. K., Zinman, B., Choi, H., Connelly, P. W., & Retnakaran, R. R. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12858 · Cited by 18
Gut peptide hormones: Importance for food intake
Näslund, E. B., Schmidt, P. T., & Hellström, P. M. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410010634 · Cited by 13
“[80] Ranganath L, Norris F, Morgan L, Wright J, Marks V.”
BackgroundZhan, X., Wang, L., Wang, Z., Chai, S., Zhu, X., Ren, W., & Chang, X. (2019) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-81 · Cited by 15
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients
Vestergaard, E. T., Hjelholt, A. J., Kuhre, R. E., Møller, N., Larraufie, P., Gribble, F. M., Reimann, F. M., Jessen, N., Holst, J. J., & Jørgensen, J. O. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02503 · Cited by 9
“Grants and fellowships: The study was supported by a postdoctoral research fellow grant (11-105283) from the Danish Council for Independent Research (Medical Sciences) and grants from the Riisfort Fonden, and the A.”
BackgroundRohden, F., Costa, C. S., Hammes, T. O., Margis, R., Padoin, A. V., Mottin, C. C., & Guaragna, R. M. V. D. C. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1279-x · Cited by 10
Brynes, A. E., Edwards, C. M. B., Ghatei, M. A., Bloom, S. R., & Frost, G. S. (2002) · Metabolism · doi:10.1053/meta.2002.29029 · Cited by 7
“The incretin glucagon-like peptide-1 [7-36] amide (GLP-1) is the most potent known endogenous gut hormone stimulant of insulin secretion in man.”
BackgroundThe discovery of peptides used for the treatment of diabetes/obesity: A personal journey
Marks, V. (2023) · Peptides · doi:10.1016/j.peptides.2023.171115 · Cited by 3
Self-citationNew Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity
Dira, L.-M., Marin, L.-M., Popa, S. G., Singer, C.-E., Coşoveanu, C. S., Donoiu, I., & Golli, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136143 · Cited by 4
Knop, F. K., Vilsbøll, T., Madsbad, S., Krarup, T., & Holst, J. J. (2007) · Diabetes · doi:10.2337/db07-1522 · Cited by 2
The Results of Prolonged Action of GLP-1 on Some Metabolic Parameters
Borkiewicz, P., Pawlak, M., & Maćkowiak, P. (2011) · Folia Biologica · doi:10.3409/fb59_1-2.13-17 · Cited by 1
Ünlü, Y., Vinales, K. L., Hollstein, T., Chang, D. C., de Baca, T. C., Walter, M. F., Krakoff, J. A., & Piaggi, P. (2022) · Obesity · doi:10.1002/oby.23584 · Cited by 3
“The lack of an increase in GLP-1 following high-carbohydrate overfeeding compared with highfat overfeeding could also be owing to a previously described attenuation of GLP-1’s response to oral carbohydrates in individuals with obesity [39–42], which is commonly attributed to an increase in plasma nonesterified fatty a…”
BackgroundInteractions of hedonic and homeostatic systems in compulsive overeating
Rossetti, C., & Boutrel, B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816207-1.00009-3 · Cited by 2
Effect of different surgical weight-loss interventions and ethnicity on GLP-1 secretion
Al-Rasheid, N. (2018) · UCL Discovery (University College London) · Cited by 1
Gastrointestinal signals regulating appetite in humans
Oesch, S. (2005) · edoc (University of Basel) · doi:10.5451/unibas-003768417 · Cited by 1
Lim, G. E. (2010) · TSpace (University of Toronto) · Cited by 1
Does Inulin Reduce Postprandial Free Fatty Acid Rebound
Tarini, J. (2010) · TSpace (University of Toronto)
Role of Fatty Acid Transport Proteins in Oleic Acid-induced Secretion of Glucagon-like Peptide-1
Poreba, M. (2011) · TSpace (University of Toronto)
The entero-insular axis and metabolic syndrome
Sarkar, J., & Chakrabarti, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00047-5
Metadata
- Authors
- RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., & MARKS, V.
- Affiliations
- Epsom Hospital (GB)
- University of Surrey (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 1999-04-01
- Volume
- 96
- Issue
- 4
- Pages
- 335-342
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2013878695
- Cited by
- 47
- References
- 31
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2019: 5 · 2018: 2 · 2017: 1 · 2015: 1 · 2014: 2 · 2012: 1
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, free fatty acids, enteroinsular axis, obesity, hyperinsulinemia, impaired glucose tolerance, acipimox, heparin, glucose-dependent insulinotropic polypeptide, GLP-1 secretion, satiety, insulin secretion
- MeSH terms
- Adult, Analysis of Variance, Dietary Carbohydrates, Glucagon-Like Peptides, Fatty Acids, Nonesterified, Female, Gastric Inhibitory Polypeptide, Glucagon, Glucose Tolerance Test, Heparin, Humans, Insulin, Models, Biological, Obesity, Peptide Fragments, Pyrazines, Triglycerides, Case-Control Studies, Neurotransmitter Agents, Postprandial Period, Area Under Curve, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.